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Abstract
Background: Complaints of unrefreshing sleep are a prominent component of chronic fatigue
syndrome (CFS); yet, polysomnographic studies have not consistently documented sleep
abnormalities in CFS patients. We conducted this study to determine whether alterations in
objective sleep characteristics are associated with subjective measures of poor sleep quality in
persons with CFS.
Methods: We examined the relationship between perceived sleep quality and polysomnographic
measures of nighttime and daytime sleep in 35 people with CFS and 40 non-fatigued control
subjects, identified from the general population of Wichita, Kansas and defined by empiric criteria.
Perceived sleep quality and daytime sleepiness were assessed using clinical sleep questionnaires.
Objective sleep characteristics were assessed by nocturnal polysomnography and daytime multiple
sleep latency testing.
Results: Participants with CFS reported unrefreshing sleep and problems sleeping during the
preceding month significantly more often than did non-fatigued controls. Participants with CFS also
rated their quality of sleep during the overnight sleep study as significantly worse than did control
subjects. Control subjects reported significantly longer sleep onset latency than latency to fall
asleep as measured by PSG and MSLT. There were no significant differences in sleep pathology or
architecture between subjects with CFS and control subjects.
Conclusion: People with CFS reported sleep problems significantly more often than control
subjects. Yet, when measured these parameters and sleep architecture did not differ between the
two subject groups. A unique finding requiring further study is that control, but not CFS subjects,
significantly over reported sleep latency suggesting CFS subjects may have an increased
appreciation of sleep behaviour that may contribute to their perception of sleep problems.
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Background
Chronic fatigue syndrome (CFS) is a complex illness
defined by unexplained persistent or relapsing fatigue for
≥ 6 months that is not attributable to exertion and is not
improved by rest. The fatigue must be accompanied by at
least 4 of 8 defining symptoms (significant worsening of
fatigue following exertion, unrefreshing sleep, impaired
memory or concentration, muscle pain, joint pain, head-
ache, tender cervical or axillary nodes, and sore throat)
and the illness must cause substantial functional impair-
ment [1]. Nearly all individuals with CFS report unre-
freshing sleep at the time of diagnosis [2-6] and self-
reported sleep problems distinguish CFS cases from
matched non-fatigued control subjects [7]. In addition,
complaints of non-refreshing sleep and difficulty getting
to sleep or staying asleep remain common (decreasing
from 95.4% to 79.2% and 81.4% to 75%, respectively,
when CFS subjects are studied at 3 yearly time points after
diagnosis [8]. These complaints and their duration satisfy
the definition for chronic insomnia as defined in an NIH
Consensus Science Statement [9]. However, while sleep
complaints are a prominent component of CFS, major
primary sleep disorders (narcolepsy and sleep apnea) are
exclusionary medical conditions that preclude the
research case definition of CFS [1,10].
Further, polysomnographic studies have not consistently
documented sleep abnormalities in people with CFS
[11,12]. These observations raise the possibility that peo-
ple with CFS perceive the quality of their sleep differently
from well individuals; i.e., the prominence of self-
reported sleep difficulties in CFS may reflect a heightened
awareness of altered sleep physiology. Altered self-percep-
tion (sensitivity to internal signals) has been suggested to
play a role in CFS [13], but few studies have explored the
relationship between self-reported sleep quality and
objective polysomnographic sleep parameters in persons
with CFS. Fossey et al., 2004, contrasted sleep parameters
obtained by polysomnography and sleep diaries, medical
diagnoses, and results of structured interview and self-
report measures between clinic-based subjects with CFS or
narcolepsy, and those with no medical or psychiatric diag-
noses. Their analyses, which included CFS subjects with
sleep disorders identified by PSG and presence of insom-
nia, described the typical symptom and impairment pro-
files of the syndrome in CFS patients [14]. A study of twins
discordant for CFS found that those with CFS were signif-
icantly more likely to report insomnia and daytime sleep-
iness than their healthy siblings yet night time
polysomnographic measurements and multiple sleep
latency test (MSLT) did not differ between the groups.
This led the authors to speculate that twins with CFS suf-
fered from sleep-state misperception insomnia according
to the 1990 International Classification of Sleep Disorders
[14-16]. The term sleep-state misperception insomnia has
been replaced by the term paradoxical insomnia, which
describes paradoxical relationships between objective and
subjective sleep assessments in such patients according to
the 2005 coding manual [17,18].
In the present study, we evaluated the relationship
between subjective and objective measures of sleep altera-
tions in persons with CFS and non-fatigued controls. As
detailed previously [12], we conducted overnight polys-
omnographic studies and daytime multiple sleep latency
evaluation of 43 individuals with CFS and 43 non-
fatigued controls. The study also included measures of
participants' long term and short-term subjective reports
of sleep quality. The following questions were addressed:
1) Are subjective sleep problems characteristic of CFS? 2)
Is there objective evidence of abnormalities of sleep in
CFS as defined by polysomnography? And, 3) Are there
associations between subjective sleep problems and
objective sleep abnormalities in persons with CFS? To
avoid referral bias, a major limitation of studies that
recruit CFS subjects from specialty clinics, we enrolled
persons with CFS and non-fatigued controls identified
from the general population of Wichita, Kansas [19,20].
We also employed standardized criteria to define CFS and
controlled for the use of medications known to affect
sleep.
Methods
Participants
This study adhered to U.S. Department of Health and
Human Services human experimentation guidelines and
received Institutional Review Board approval from the
CDC and collaborating institutions. All participants gave
informed consent.
Between January and July 2003, we conducted a 2-day in-
hospital study of adults identified with CFS from the gen-
eral population of Wichita [19]. The in-hospital study
enrolled people who participated in the 1997 through
2000 Wichita Population-Based CFS Surveillance Study
[20]. The primary objective of the Surveillance Study was
to estimate the baseline prevalence and 1-year incidence
of CFS in Wichita, Kansas. Participants in the in-hospital
study were fatigued adults with medically/psychiatrically
unexplained chronic fatigue identified during the surveil-
lance study. Fifty-eight participants had been diagnosed at
least once with CFS and 59 had unexplained chronic
fatigue that was not CFS. Controls were randomly selected
from the cohort who participated throughout surveil-
lance, who did not have medical or psychiatric exclusions,
and who had not reported fatigue of at least 1-month
duration; they were matched to CFS cases on sex, age,
race/ethnicity, and body mass index. Upon admission to
this study, subjects were re-evaluated for CFS symptoms
and exclusionary medical and psychiatric conditions (dis-BMC Neurology 2007, 7:40 http://www.biomedcentral.com/1471-2377/7/40
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cussed below). The 43 who, at the time of the in-hospital
study, met 1994 criteria for CFS (discussed below) com-
prise the cases in this report. Control subjects were 43
individuals who had never reported fatigue during the
surveillance study, who were not fatigued at the time of
entry into this in-hospital study and who had no exclu-
sionary medical or psychiatric condition identified at the
time of the study (following section). Because current
classification of CFS was not completely in accord with
recruitment classification, strict matching was not main-
tained, though cases and controls were demographically
comparable. Thirty-six (84%) of the 43 with CFS and 38
(88%) of the 43 controls were women; most (40 CFS and
42 controls) were white; their mean ages were 50.6 and
50.3 years, respectively; and body mass index was 29.4
and 29.3, respectively.
Assessment and classification of CFS
We classified participants as having CFS at the time of the
study based on the empirical application [19] of the 1994
CFS research case definition [1]. We used the Multidimen-
sional Fatigue Inventory (MFI) [21] to evaluate fatigue sta-
tus; we measured functional impairment with the Medical
Outcomes Survey short form-36 (SF-36) [22]; and, we
used the CDC Symptom Inventory [23] to assess fre-
quency and severity of the 8 CFS defining symptoms. We
defined severe fatigue as ≥ medians of the MFI general
fatigue (≥ 13) or reduced activity (≥ 10) scales. We defined
substantial functional impairment as scores lower than
the 25th percentile of published US population on the
physical function (≤ 70), or role physical (≤ 50), or social
function (≤ 75), or role emotional (≤ 66.7) subscales of
the SF-36. Finally, subjects reporting ≥ 4 symptoms and
scoring ≥ 25 on the Symptom Inventory Case Definition
Subscale were considered to have substantial accompany-
ing symptoms.
To assess whether medical conditions exclusionary for
CFS (including untreated hypothyroidism, sleep apnea, or
narcolepsy) had developed since the surveillance study,
participants provided a standardized past medical history
and a listing of current medications, underwent a stand-
ardized physical examination, and provided blood and
urine for routine analysis. Medications that affect sleep
were considered 'sleep medications' for the purpose of
analysis and include: primary hypnotics (zolpidem,
temazepam), narcotic analgesics (e.g., hydrocodone, oxy-
codone, propoxyphene), anti-depressants (e.g., citalopram,
amitriptyline, imipramine, escitalopram, bupropion, ven-
lafaxine, sertraline, paroxetine, fluoxetine), anti-anxiety
(alprazolam),  anti-histamines  (e.g., diphenhydramine,
chlorpheneramine, promethazine), decongestants  (e.g.,
pseudoephedrine, guaifenesin), anti-convulsants  (e.g.,
topiramate, clonazepam), anti-sleep phase disorder (mela-
tonin),  blood pressure controlling (e.g., clonidine, mido-
drine),  anti-psychotics  (e.g., quetiapine, ziprasidone),
stimulants  (e.g., methylphenidate, modafinil), peristaltic
stimulants  (metoclopramide), and muscle relaxants
(cyclobenzaprine).
To identify psychiatric conditions exclusionary for CFS
(current melancholic depression, current and lifetime
bipolar disorder or psychosis, substance abuse within 2
years and eating disorders within 5 years), licensed and
specifically trained psychiatric interviewers administered
the Diagnostic Interview Schedule for Axis I psychiatric
disorders.
We classified participants meeting the 3 criteria (MFI, SF-
36, and Symptom Inventory) for CFS and in whom no
exclusionary medical (including sleep) or psychiatric con-
ditions were identified as having CFS. Participants whose
scores were in the normal range on all of the above men-
tioned instruments and who had no exclusionary medical
or psychiatric conditions identified were classified as non-
fatigued. Persons with exclusionary medical or psychiatric
conditions were not included in the analysis.
Objective measures of sleep alterations
Sleep studies were conducted in a 4-bed clinical research
unit at Wesley Medical Center, Wichita, Kansas [12].
These sleep studies consisted of polysomnography on
night #1, Multiple Sleep Latency Tests (MSLT) during the
following day, and repeat polysomnography on night #2.
Patients were asked to arrive 3 hours before their typical
bedtime on night #1 to allow adequate time for electrode
application and standard bio-calibrations. "Lights out"
and "Lights on" time were 22:00 and 7:00, respectively.
MSLT began at 11:00 the following morning and con-
sisted of three additional naps at 13:00, 15:00, and 17:00.
Daytime sleepiness was measured with the MSLT, which
has demonstrated objective sensitivity to the effects of
sleep deprivation, sleep fragmentation, sleep restriction,
insufficient sleep hypersomnia, and in disease states such
as sleep apnea and narcolepsy [24,25]. Multiple sleep
latency tests were performed and scored according to
standard guidelines [26,27] with the exception that four
naps were recorded. The mean sleep latency on the MSLT
was defined as the mean time from lights out to the first
30-second epoch scored as sleep. A sleep onset REM was
defined as one or more epochs of REM sleep occurring
within 15 minutes of the first epoch scored as sleep. We
considered a mean sleep latency <5 min as pathological
sleepiness, scores between 5–10 min as a degree of day-
time sleepiness (borderline abnormal), and scores of
10–20 min as normal and a lack of daytime sleepiness.
Because mean values on the MSLT may adversely be
affected by a spurious sleep latency on a single nap oppor-
tunity [28] possibly due to what might be perceived asBMC Neurology 2007, 7:40 http://www.biomedcentral.com/1471-2377/7/40
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stressful inter-nap activities [29], median values were also
computed for each subject.
Measures of sleep architecture and diagnoses of primary
sleep disorders were based upon data from MSLT and the
second nocturnal polysomnography (to allow for sleep-
lab habituation). Clinical outcomes of polysomnographic
assessment and MSLT included obstructive sleep apnea,
periodic limb movements, narcolepsy, insufficient sleep
syndrome, primary/secondary insomnia, delayed sleep
phase syndrome, bruxism, central sleep apnea, and upper
airway resistance syndrome.
The polysomnographic outcome variables used in our
analyses included: total sleep time (TST) (in min), sleep effi-
ciency (% of time spent in bed asleep), the percentage of TST
spent in non-REM (NREM) and REM sleep, latency to sleep
onset (in min) to three consecutive epochs of sleep, and
REM latency, defined as the time between the first epoch
of any stage of sleep and the first epoch of REM-sleep. Brief
arousals  were scored following criteria set forth by the
American Academy of Sleep Medicine, and the number of
arousals expressed as a rate per hour of sleep adjusted for
TST. Periodic leg movements both with and without accom-
panying arousals, were scored according to conventional
criteria [30], and expressed as an index of the rate of leg
movements per hour of sleep, and a separately derived
index of those accompanied by an American Academy of
Sleep Medicine -defined arousal [31]. We further recorded
alpha intrusion, which was noted in review of 30-second
segments.
Polysomnography data were scored by an Emory Univer-
sity registered polysomnology technologist and inter-
preted by an Emory University Department of Neurology
American Board of Sleep Medicine certified physician
[12].
Assessment of subjective sleep quality and sleepiness
During the afternoon of their arrival at the hospital, sub-
jects completed a self-administered questionnaire that
explored themes and beliefs regarding sleep. The first two
sleep specific questions, taken from the CDC Symptom
Inventory [23], queried frequency and intensity of unre-
freshing sleep and problems sleeping during the past
month. A score of 0 reflected no difficulty with unrefresh-
ing sleep or no problems sleeping and the maximum
score of 16 indicated the problem had occurred all the
time and was severe [see [23]]. The remaining 24 items of
this questionnaire came from the Epworth Sleepiness
Scale [32], which evaluates levels of excessive daytime
sleepiness, and from the Toronto Sleep Assessment Ques-
tionnaire (SAQ©) [33], which measures self-reported sleep
quality.
Subjects completed four questionnaires (the Nap Book-
lets) after each nap on day 1, which assessed latency to fall
asleep during each nap. Subjects also completed two ques-
tionnaires (the Sleep Booklets) the morning after each
overnight study, which evaluated 1) perceived sleep qual-
ity the night before on a visual analogue scale from 'Best
possible sleep' (equals 0) to 'Worst possible sleep' (equals
140); 2) latency to fall asleep (in min); and 3) total sleep
time (in min).
Statistical analysis
Differences in categorical demographic data between CFS
cases and non-fatigued controls were evaluated by Chi-
Square or Fisher's exact test and continuous variables were
compared by the t-test. Chi-Square test was also used for
comparison CFS cases and non-fatigued controls in sleep
study alterations. We used standard logistic regression
analysis to regress CDC Symptom Inventory scores (unre-
freshing sleep, problems sleeping) as well as Sleep Booklet
scores (latency to fall asleep, total sleep time, sleep qual-
ity) and sleep medication use (yes/no) on case status
(CFS/non-fatigued). Data from all participants was evalu-
ated by logistic regression; in addition the subgroup of
subjects with no alterations noted in sleep studies (nor-
mal sleep) were evaluated separately.
A two factor analysis of variance (ANOVA) using a general
linear model was employed to measure the association
between cases status and medication use (yes/no) with
polysomnographic variables. Log transformed values of
polysomnographic variables were used when necessary to
satisfy the assumption of normally distributed outcomes.
Mean values for each polysomnographic variable were
adjusted for medication use by utilizing the least squares
method.
Paired samples t-tests were used to compare 1) mean sleep
latency, as measured by the MSLT, and mean sleep
latency, as evaluated by the Nap Booklets and 2) latency
to fall asleep and total sleep time as measured by noctur-
nal polysomnography with latency to fall asleep and total
sleep time as measured by the Sleep Booklets. Compari-
sons were done separately for the group of subjects with
CFS and for the non-fatigued controls. P-values for the
paired  t-tests were adjusted for multiple comparisons
using both a Bonferroni correction and by computing a
false discovery rate [34].
Sleep questionnaire data from the SAQ© and the Epworth
sleepiness scale were z-transformed for multivariate anal-
yses. We used Principal Component Analysis (PCA) [35]
with varimax rotation to evaluate which constellation of
sleep symptoms represented the majority of the variance
in sleep symptoms. Two-factor ANOVA was applied for
comparison of factorial scores of sleep questionnaireBMC Neurology 2007, 7:40 http://www.biomedcentral.com/1471-2377/7/40
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items between CFS and non-fatigued groups, controlling
for sleep medication use (yes/no). Comparison of facto-
rial scores was done for all participants as well as for the
subgroup of subjects with normal sleep studies.
Statistical significance for all tests was set at the 5% level.
All statistics were computed using SPSS 12.0 (SPSS Inc,
Chicago, IL).
Results
Clinically significant apnea and narcolepsy (exclusionary
for CFS) were diagnosed in 11 subjects based on overnight
and daytime polysomnographic studies [12]. These sub-
jects were not included in this analysis.
The remaining CFS and control subjects were demograph-
ically comparable. Thirty (85%) of the 35 with CFS and 36
(90%) of the 40 controls were women; 32 CFS (91%) and
all controls were white; their mean ages were 50.3 (range
27 – 69) and 50.5 (range 32 – 65) years, respectively; and
mean body mass index was 28.7 and 29.2, respectively.
Medication use was more common in CFS subjects com-
pared to non-fatigued controls; 20 CFS subjects (57%)
compared to 5 control subjects (13%) took medications
that alter sleep.
Polysomnographic findings in CFS and non-fatigued
Detailed polysomnographic findings have been reported
in detail [12]. In brief, previously undiagnosed sub-clini-
cal sleep disorders occurred similarly in both CFS and
non-fatigued controls (Table 1). Minimal obstructive
sleep apnea and periodic limb movements were the most
common alterations and occurred similarly among those
with CFS and the controls. MSLT results were also compa-
rable between the two groups. Finally, there were no sta-
tistically significant differences in standard
polysomnographic measurements between those with
CFS and non-fatigued controls on either night 1 or night
2. Since the first night served as an adaptation to the sleep
laboratory, Table 2 summarizes only the night-2 data
adjusted for medication use. In addition, each group
appeared to experience similar periods of wakefulness
during the study night as recorded in the % wakefulness
during the sleep period.
Sleep symptoms in CFS and non-fatigued
Our analysis included two questionnaire items from the
CDC Symptom Inventory that assess subjective sleep
qualities over the preceding month, unrefreshing sleep
and problems sleeping (getting to sleep, not sleeping
through the night, or waking up on time), as well as one
question from the Sleep Booklet, evaluation of sleep qual-
ity (best possible sleep to worst possible sleep) during the
PSG. In a logistic regression analysis, we found an associ-
ation of CFS with higher frequencies of symptoms of
unrefreshing sleep and problems sleeping (p < .001 for
each item) as well as worse ratings of sleep quality (p <
.05); these associations remained after adjusting for use of
medications that affect sleep.
Among subjects with normal objective sleep studies, those
with CFS still reported significantly higher frequencies of
unrefreshing sleep and problems sleeping than did non-
fatigued controls (p < .001 for each item). In addition,
CFS subjects with normal  sleep studies also rated their
quality of sleep during night #2 significantly worse than
non-fatigued controls (p < .05).
Perception versus polysomnographic assessment of sleep 
in CFS and non-fatigued
No significant differences between self-reported, as evalu-
ated by the Nap Booklet, and the objective mean sleep
latencies, recorded by the MSLT, were found for CFS sub-
jects (Nap booklet score (± SE): 9.3 (± 0.9) minutes versus
MSLT score : 7.2 (± 0.7) minutes, respectively; t (7) = 1.7.
p = .13). In contrast, in non-fatigued controls, self-
Table 1: Sleep disorders in CFS and non-fatigued controls
Sleep Disorders† CFS (35) NF (40) p*
Obstructive Sleep Apnea (borderline) 3 (8%) 3 (7%) /
Periodic Limb Movements 7 (20%) 8 (20%) NS
Insufficient Sleep Syndrome 1 (2%) 0 NS
Delayed Sleep Phase Syndrome 01  ( 2 % ) N S
MSLT Normal 16 (45%) 16 (40%) /
MSLT Borderline 13 (37%) 15 (37%) NS
MSLT Pathological 6 (17%) 9 (22%) NS
Any Sleep Study Alteration 26 (48%) 28 (52%) NS
* Chi-square test.
NF = Non-fatigued; MSLT = Multiple Sleep Latency Test.
† No cases of Bruxism, Central Sleep Apnea or Upper Airway
Resistance Syndrome were identified.BMC Neurology 2007, 7:40 http://www.biomedcentral.com/1471-2377/7/40
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reported mean sleep latency was significantly longer than
recorded mean sleep latency, MSLT score (± SE): 10.8 (±
1.5) min versus Nap booklet score :5.8 (± 0.6) min,
respectively; t(16) = 2.9, p < .01).
Similarly, self-reported mean latency to fall asleep in non-
fatigued controls, as reported in the Sleep Booklets, was
significantly longer than mean latency to fall asleep, as
measured by overnight polysomnography. These differ-
ences were found both on night #1 and night #2 in con-
trol subjects, but were more pronounced on night #1. The
mean latency to fall asleep on night #1 was 18.9 (± 3.5)
minutes as measured by PSG, versus mean latency to fall
asleep night described in the Sleep booklet 31.8 (± 5.2)
minutes (t(38) = 3.05, p < .005). The mean latency to fall
asleep on night #2 was 16.6 (± 3.5) minutes as measured
by PSG, versus latency to fall asleep night described in the
Sleep booklet of 23.7 (± 4.1) minutes (t(38) = 2.4, p <
.02). In contrast, no significant differences between sub-
jective and objective latency to fall asleep during over-
night polysomnography, were found in CFS subjects on
either night #1 or night #2. These results remained even
after excluding those subjects taking medications that
affect sleep. There was no significant difference in total
sleep time, as estimated by the Sleep Booklets, and total
sleep time, as measured by overnight polysomnography,
in either non-fatigued controls or CFS subjects.
Using the conservative Bonferroni correction for multiple
comparisons at the α = .05 level, only the difference in
night #1 sleep latencies in control subjects would remain
significant. However, using the method of Benjamini and
Hochberg and controlling the false discovery rate to <
10%, then all 3 of the p-values reported above are still sig-
nificant [33] Together, these data suggest that altered per-
ception of the latency to sleep onset is common in non-
fatigued controls, but not in CFS patients.
Considering all items assessed by the SAQ© and Epworth
sleepiness scales, Principal Component Analysis (PCA)
revealed six factors that accounted for the majority of var-
iability in responses on the sleep questionnaire items.
Table 3 shows the individual items comprising the six fac-
tors after a Varimax rotation with Kaiser normalization,
the mean factor scores, and p-values for the differences
between CFS and non-fatigued controls. A higher mean
value for a factorial score represents more endorsement of
the sleep questionnaire items comprising the factor (i.e.
more sleep complaints). Factor score names were assigned
to groups of questions comprising the different groupings
based on the domains covered by the individual ques-
tions even though the questions were not designed with
specific disorders or disturbances in mind. CFS cases had
significantly higher scores in the Insomnia and Physical/
Somatic factors compared to non-fatigued controls. CFS
cases also had notably higher scored on the Sleepiness fac-
tor, although the difference was not statistically signifi-
cant.
Differences in perception of sleep quality were even more
pronounced between CFS cases and controls with normal
objective sleep studies. CFS cases not only had signifi-
cantly higher scores in the Insomnia  (CFS: 0.51, non-
fatigued: -0.56, p = 0.001) and Physical/Somatic  (CFS:
0.41, non-fatigued: -0.42, p = 0.013) factors, but also in
the Sleepiness factor (CFS: 0.39, non-fatigued: -0.27, p =
.004).
Discussion
The major finding of this study is the documentation of
the extent and nature of sleep complaints experienced by
CFS subjects compared to non-fatigued controls in the
absence of differences in quantitative polysomnography
and multiple sleep latency testing between the two
groups. These findings are in agreement with previous
clinic-based studies indicating that CFS patients perceive
poor sleep in the absence of objective underlying sleep
pathology [11,12,15,16]. However, the somewhat para-
doxical observation that controls and not CFS subjects,
overestimated the time to fall asleep, has not been previ-
ously reported and deserves further exploration. This find-
ing suggests that CFS subjects may more closely monitor
their sleep behaviour and that may contribute to their per-
ceived sleep problems. It is also possible that persons with
CFS are more accurate in their perceptions of their gener-
ally impaired sleep than people who do not have insom-
Table 2: Sleep architecture in CFS and non-fatigued controls – 
Night 2 adjusted for medication use
CFS n = 35 NF n = 40 p-value**
Adjusted 
Mean*
Adjusted 
Mean*
Total sleep time (min) 400.3 407.9 0.52
Sleep period time (min) 453.8 457.8 0.79
Latency to sleep onset (min) 21.3 17.1 0.47
REM latency (min) 98.4 106.8 0.40
Sleep efficiency (%) 88.3 90.2 0.32
Wake after onset (min) 53.8 44.0 0.69
Wake % Sleep Period 11.7 9.8 0.72
# Arousals 105.7 110.2 0.81
Arousal index 15.9 16.3 0.82
Stage 1 (% TST) 9.6 9.5 0.79
Stage 2 (% TST) 48.2 50.8 0.28
Stage 3/4 (% TST) 19.9 17.4 0.20
REM (% TST) 22.3 23.3 0.98
Alpha intrusion 0.29 0.49 0.11
*Mean values adjusted for medication use (yes/no).
** p-values generated using 2-factor analysis of varianceBMC Neurology 2007, 7:40 http://www.biomedcentral.com/1471-2377/7/40
Page 7 of 9
(page number not for citation purposes)
nia (but may sleep badly from time to time). This finding
should be validated in further studies.
Even though identification of insomnia per se was not a
goal of the study, it is interesting to note that CFS subjects
in this study who were identified by the presence of a pro-
longed syndromic illness and its consequences also ful-
filled a general definition for insomnia [9,18,36]. The
symptom variables related to sleep (unrefreshing sleep
and the 3 components of problems sleeping- getting to
sleep, not sleeping through the night, or waking up on
time) were identified by the patients themselves during
the construction of the CFS symptom inventory [23]. Do
these observations suggest that the CFS subjects have a
problem with sleep efficacy, or that their descriptions of
symptom association or our efforts to obtain information
from them are inadequate? Are the CFS subjects identify-
ing their impairments in terms of sleep based on the types
of questions being asked with responses indicative of
sleep problems not detected in the usual measures of
sleep architecture?
These findings argue against the importance of readily
identifiable sleep pathology contributing to the symp-
toms of CFS in the majority of CFS subjects. However,
sleep disorders that may respond to clinical intervention
should be evaluated in patients complaining of fatigue,
and formal sleep studies are required in the evaluation of
patients with suspected sleep disturbances. In clinical
practice these disorders would have been considered as
temporary exclusions of CFS and the patient re-evaluated
after clinical re-evaluation [8]. New clinical interventions
in CFS patients await further delineation of possible
mechanisms required to explain these differences, but
they will likely be based on pharmacological and/or
behavioural modalities. However, such interventions
need to be based on a better understanding of sleep phys-
iology and the influences of chronic illness and exclusion
of primary sleep disorders.
[0]Besides the theoretical issues addressed above, the
present study is not without practical limitations. First,
due to stringent selection criteria, our sample size was
small, especially considering the number of variables
examined. This circumstance limited the power to detect
Table 3: Mean (SD) factorial scores and p-values for sleep questionnaire items in CFS and non-fatigued subjects
Factor pattern on sleep questionnaire items CFS (n = 35) NF (n = 40) P *
Mean factor scores (SD)† Mean factor scores (SD)
F1 Insomnia 0.54 (0.8) -0.48 (0.9) .000
"How often trouble sleeping", "Waking up before you wanted to", "Sleeping 
for less than 5 hours", "Difficulty falling asleep", "Repeated awakenings", 
"Waking up not feeling refreshed", "Restlessness during sleep"
F2 Sleepiness 0.27 (1.2) -0.24 (0.5) .060
"Falling asleep while sitting and talking", "Falling asleep while doing 
something, such as driving or talking", "Falling asleep in a car while stopped 
in traffic", "Falling asleep while sitting and reading", "Falling asleep as a 
passenger in a car", "Falling asleep while sitting quietly after a lunch", "Falling 
asleep while sitting inactive in a public place", "Trouble staying awake"
F3 Physical/Somatic 0.54 (1.0) -0.48 (0.5) .001
"Nightmares or waking up frightened or crying out loud", "Waking up with 
aches, pains, or stiffness", "Sleeping more than nine hours", "Taking 
medication for sleep"
F4 Apnea "Interruptions to your breathing during sleep", "Falling asleep 
while lying down to rest in the afternoon"
0.09 (0.7) -0.08 (1.2) .865
F5 Body Clock 0.13 (1.2) -0.11 (0.7) .610
"Working shifts", "Irregular bed time and/or wake-up time during the work 
week or weekdays"
F6 Nasal Obstruction 0.13 (1.1) -0.12 (0.8) .318
"Loud snoring"
* 2-factor ANOVA, controlling for medication that influences sleep.
† A higher factor score represents more agreement on the sleep questionnaire items comprising the factor (i.e. more sleep complains)BMC Neurology 2007, 7:40 http://www.biomedcentral.com/1471-2377/7/40
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more subtle differences in responses to sleep question-
naire items between groups. Both CFS subjects and con-
trols showed moderately impaired sleep quality (being in
a research setting likely impaired sleep quality equally for
both groups) and polysomnography is not an optimal
measure of insomnia. Further studies with larger sample
sizes are clearly warranted. Second, while sleep-altering
medications were frequently used by both CFS subjects
and controls, their use was more common among CFS
subjects. Prescribed medications in CFS subjects may in
turn have influenced CFS subjects' reports of sleep quality.
Many published studies of sleep in persons with CFS do
not consider medication use. Our attempt to statistically
adjust for differences in use of medications that affect
sleep as a binary measure (use/non-use) might be inade-
quate to completely control for the confounding effect of
medication use. However, our small sample size pre-
cluded conducting a stratified analysis among cases and
controls who did and did not use medications that alter
sleep or whether they medications induced or inhibited
sleep. Finally, the mean duration of illness among CFS
cases in this population was 7.3 years [19]. Thus, findings
in this study of prevalent CFS cases may not be applicable
to those with a shorter duration of illness.
Conclusion
These findings suggest that alterations in standard objec-
tive sleep parameters do not explain the etiology of symp-
toms of unrefreshing sleep and presence of sleep
problems reported by persons with CFS who do not have
readily diagnosable sleep disorders. Further studies exam-
ining the causes of apparent altered sleep-state perception
may be helpful in understanding CFS.
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